NCT01840449View on ClinicalTrials.gov

Somatuline Predictive Factors in Acromegaly and NET

CompletedOBSERVATIONAL
Enrollment

156

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

July 31, 2016

Study Completion Date

May 31, 2017

Conditions
AcromegalyNeuroendocrine Tumours
Interventions
DRUG

Somatuline Autogel® 60, 90 or 120 mg

Trial Locations (3)

Unknown

University Hospital of Vienna, Vienna

ENDOC, Hamburg

University Hospital Basel, Basel

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT01840449 - Somatuline Predictive Factors in Acromegaly and NET | Biotech Hunter | Biotech Hunter